Pancreatic Cancer Research

ResearcherHarold C. Simmons Comprehensive Cancer CenterActive in the last 2 years

Todd Anthony Aguilera

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3734-3758; OpenAlex author ID A5036054930, A5158539426. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
103
Papers, trials and grants by year

2019: 1 paper · 2020: 2 papers · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 6 papers · 2026: 2 papers

Papers 15

  1. Immune Stromal Components Impede Biological Effectiveness of Carbon Ion Therapy in a Preclinical Model of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1535-7163.mct-25-0501↗
  2. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  3. Evolving Paradigms in the Treatment of Oligometastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12029-024-01145-0↗
  4. NRG Oncology International Consensus Contouring Atlas on Target Volumes and Dosing Strategies for Dose-Escalated Pancreatic Cancer Radiation Therapy. Co-author DOI 10.1016/j.ijrobp.2024.10.026↗
  5. Quality and Quantity: Dual Benefits of Ablative Radiation in Oligometastatic Pancreatic Cancer. Co-author DOI 10.1016/j.semradonc.2025.07.004↗
  6. Defective homologous recombination and genomic instability predict increased responsiveness to carbon ion radiotherapy in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00800-4↗
  7. Post-operative patterns of failure and outcomes reveal opportunities to optimize treatment of recurrent pancreatic cancer Last author DOI 10.1101/2025.11.08.25339815↗
  8. Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-24-3582↗
  9. Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer Patients. Co-author DOI 10.1245/s10434-023-14805-5↗
  10. Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design. First author DOI 10.2217/fon-2022-1219↗
  11. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-control… Co-author DOI 10.1016/s1470-2045(23)00478-3↗
  12. Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes. Last author DOI 10.1016/j.ijrobp.2022.07.019↗
  13. Targeting TAM to Tame Pancreatic Cancer. Co-author DOI 10.1007/s11523-020-00751-9↗
  14. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic… Co-author DOI 10.1016/j.ijrobp.2020.09.022↗
  15. Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma. First author DOI 10.6004/jnccn.2019.7322↗

Closest collaborators

The 25 strongest of 103 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ahmed M. Elamir · 5 shared papers, 2022–2025 · strength 1.13
  2. Herbert J. Zeh · 6 shared papers, 2019–2025 · strength 0.93
  3. Patricio Marcelo Polanco · 5 shared papers, 2022–2026 · strength 0.89
  4. Nina Niu Sanford · 5 shared papers, 2019–2025 · strength 0.83
  5. Ethan Bernard Ludmir · 3 shared papers, 2023–2025 · strength 0.78
  6. Joseph M. Herman · 4 shared papers, 2020–2025 · strength 0.59
  7. Muhammad Shaalan Beg · 4 shared papers, 2019–2025 · strength 0.54
  8. Syed Mohammad Ali Kazmi · 3 shared papers, 2022–2025 · strength 0.54
  9. Matthew R. Porembka · 3 shared papers, 2022–2025 · strength 0.54
  10. Mokenge Peter Malafa · 3 shared papers, 2023–2026 · strength 0.50
  11. Katy L. Swancutt · 2 shared papers, 2025–2026 · strength 0.49
  12. Anthony J. Davis · 2 shared papers, 2025–2026 · strength 0.49
  13. Brock J. Sishc · 2 shared papers, 2025–2026 · strength 0.49
  14. Shubham Pant · 3 shared papers, 2020–2025 · strength 0.44
  15. Ching-Wei David Tzeng · 3 shared papers, 2020–2025 · strength 0.44
  16. Peter Q. Leung · 2 shared papers, 2025 · strength 0.41
  17. Salwan S. Al Mutar · 2 shared papers, 2025 · strength 0.41
  18. Sarah E. Hoffe · 3 shared papers, 2020–2024 · strength 0.40
  19. Brian G. Czito · 3 shared papers, 2020–2026 · strength 0.40
  20. Marsha Reyngold · 2 shared papers, 2025–2026 · strength 0.37
  21. Amol Kumar Narang · 2 shared papers, 2025–2026 · strength 0.37
  22. Eugene Jon Koay · 2 shared papers, 2023–2025 · strength 0.35
  23. Adam Charles Yopp · 2 shared papers, 2024–2025 · strength 0.34
  24. Megan Wachsmann · 2 shared papers, 2024–2025 · strength 0.34
  25. Robert A. Wolff · 2 shared papers, 2023–2026 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.